Hims & Hers Health HIMS
United StatesHealthcare · Drug Manufacturers - Specialty & GenericUSD
31.15 USD (+5.5%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
Hims & Hers Health, Inc. is a digital health company that offers a telemedicine platform and an online pharmacy for the prescription and delivery of medications and wellness products, primarily in the United States.
Key points
from its scores- ✓Strong growth9.5
- ✕Poor share-price trend0.3
- ✕Unfavourable risk and backdrop0.5
- ✕Little or no dividend1.5
AI analysis
bottom line, main risk, context and newsGrowth and cash are attractive, but the lack of profitability and demanding valuation require proof that the model can scale towards sustainable profits.
Hims & Hers shows exceptional revenue growth of 38.20%, but its profitability is negative (operating margin of -12.75%, ROE of -32.03%), reflecting a high-investment strategy to gain market share. Its balance sheet is very solid, with a net cash position (Net Debt/EBITDA of -69.29), providing financial flexibility. However, the valuation (forward P/E of 40.07) already discounts very optimistic future growth, and momentum is very negative (-49.01%), suggesting the market is questioning its ability to achieve profitability.
The main risk is the inability to translate its high revenue growth into profitability, given its negative operating margin and increasing regulatory pressure on digital drug prescription in the US.
Context and risks
Hims & Hers operates in the digital health and online pharmacy sector in the United States, a market with increasing regulatory scrutiny. The company faces specific risks from its business model, such as the prescription of medications through digital platforms, which is being reviewed by the FDA and other state agencies. Furthermore, its dependence on digital advertising and social media to acquire customers exposes it to changes in platform policies and potential scrutiny over the marketing of pharmaceutical products.
Is Hims & Hers Health stock cheap or expensive?
at the analysis dateOn Price / sales, it trades 22% below the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| Price / book | 21.3 | 4.1 | +418% |
| Price / sales | 2.7 | 3.4 | −22% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 5.0 out of 10 (median for Healthcare: 4.7).
Average analyst target: 31.15 USD, +5.5% versus the price.
A discount may reflect more risk or slower growth than its sector: Financial health 5.7 (sector 6.5), Growth 9.5 (sector 6.6).
Classic formulas with standard assumptions (5.0% growth, 8-9% discount rate). Indicative only: they change a lot with the assumptions and are not a recommendation.
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 40.1
- EV / EBITDA
- −746.5
- Price / book
- 21.3
- Price / sales
- 2.7
- PEG
- 2.69
- Market cap
- 6.9B USD
- Enterprise value
- 7.6B USD
Profitability
- ROE
- −32.0%
- ROA
- −2.2%
- ROIC (approx.)
- −17.6%
- Gross margin
- 69.5%
- Operating margin
- −12.8%
- Net margin
- −5.5%
- Free cash flow
- 849.4M USD
- FCF yield
- 12.3%
Solvency
- Total debt
- 1.5B USD
- Net debt
- 705.2M USD
- Cash
- 841.0M USD
- EBITDA
- −10.2M USD
- Net debt / EBITDA
- −69.29
- Debt / equity
- 477.13
- Current ratio
- 0.93
- Quick ratio
- 0.82
Growth
- Revenue growth
- +38.2%
- EPS (TTM)
- −0.64 USD
- EPS (forward)
- 0.74 USD
Dividend
- Dividend yield
- 0.0%
- Payout
- 0.0%
Risk and market
- Beta
- 2.43
- Analyst consensus
- Hold (13)
- Target price
- 31.15 USD
- 52-week range
- 13.74 – 65.30
Recent news
All HIMS news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about Hims & Hers Health
Is Hims & Hers Health stock cheap or expensive?
On Price / sales, it trades 22% below the Healthcare median. Valuation score: 5.0 out of 10 (median for Healthcare: 4.7). Average analyst target: 31.15 USD, +5.5% versus the price. This is not investment advice.
What score does Hims & Hers Health get on MeridIAn Screener?
It scores 4.0 out of 10, rank 1,968 of 2,130 (better than 7% of the companies analysed). Its strongest category is Growth (9.5) and its weakest, Momentum (0.3). Analysis of 08/10/2026.
How much is Hims & Hers Health worth on the stock market?
Its market capitalisation is 6.9B USD and its enterprise value, debt included, is 7.6B USD.
How much debt does Hims & Hers Health have?
Its net debt (debt minus cash) is 705.2M USD.
Does Hims & Hers Health pay a dividend?
It pays no dividend, or almost none.
How has Hims & Hers Health stock performed over the last year?
It has fallen 45.2% over the last year, excluding dividends. Over the last 52 weeks it has traded between 13.74 and 65.30 USD. Past performance does not guarantee future results.
What do analysts think of Hims & Hers Health?
13 analysts cover it; their average recommendation is “Hold” and their average target is 31.15 USD (+5.5% versus the price). It is an estimate, not market data.